TRAIL/Apo2L is a cytotoxic protein, which activates rapid apoptosis in tumor cells, but not in normal cells. TRAIL-induced apoptosis is achieved through binding to two death-signaling receptors, DR4 and DR5. These receptors belong to the TNFR superfamily of transmembrane proteins, and contain a cytoplasmic "death domain", which activates the cell's apoptotic machinery. The full length human TRAIL/Apo2L is a 281 amino acid protein, consisting of a 17 amino acid cytoplasmic domain, a 21 amino acid transmembrane domain, and a 243 amino acid extracellular domain. Recombinant Human soluble TRAIL/Apo2L is a 168 amino acid polypeptide (19.6 kDa), consisting of the TNF-homologous portion of the extracellular domain of the full length TRAIL/Apo2L protein.
TNF-Related Apoptosis-Inducing Ligand, TNFSF10, Apo2 Ligand, TL2
MRERGPQRVA AHITGTRGRS NTLSSPNSKN EKALGRKINS WESSRSGHSF LSNLHLRNGE LVIHEKGFYY IYSQTYFRFQ EEIKENTKND KQMVQYIYKY TSYPDPILLM KSARNSCWSK DAEYGLYSIY QGGIFELKEN DRIFVSVTNE HLIDMDHEAS FFGAFLVG
≥ 98% by SDS-PAGE gel and HPLC analyses.
Assay #1: Determined by its ability to induce apoptotic cell death in TRAIL-sensitive U343MG cells. The expected ED50 for this effect is 1.0-3.0 ng/ml.
Assay #2: Measured by its ability to induce apoptosis in LN-18 cells (human glioblastoma cells). The expected ED50 for this effect is 0.8-2.0 ng/ml.
This product has been tested against the WHO standard. International Unit information can be found here.
Calculated Molecular Weight:
Not for human use.